BVS · Bioventus Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $132.09M | - | $138.65M | $147.66M | $123.88M | - | $138.96M | $151.22M | $129.46M | - |
| Cost of Revenue | $41.32M | - | $44.42M | $45.57M | $40.82M | - | $45.41M | $47.58M | $41.08M | - |
| Gross Profit | $90.77M | - | $94.23M | $102.09M | $83.06M | - | $93.55M | $103.64M | $88.38M | - |
| R&D | $2.47M | - | $2.92M | $3.17M | $3.01M | - | $3.81M | $3.99M | $2.60M | - |
| SG&A | $78.33M | - | $78.66M | $79.11M | $73.50M | - | $81.09M | $94.78M | $78.41M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $11.21M | - | $1.40M | $1.44M | $11.87M | - | $2.06M | $2.06M | $11.79M | - |
| Operating Income | $8.42M | - | $11.25M | $18.37M | $4.87M | - | $4.07M | ($29.37M) | $5.33M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $571.0K | - | $664.0K | $1.04M | ($95.0K) | - | $589.0K | ($7.34M) | $907.0K | - |
| Net Income | $3.11M | - | $3.15M | $7.46M | ($2.64M) | - | ($4.82M) | ($23.99M) | ($4.57M) | - |
| EPS - Basic | $0.05 | - | $0.05 | $0.11 | ($0.04) | - | ($0.07) | ($0.37) | ($0.07) | - |
| EPS - Diluted | $0.04 | - | $0.05 | $0.11 | ($0.04) | - | ($0.07) | ($0.37) | ($0.07) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $35.85M | $51.24M | $42.16M | $32.91M | $22.80M | $41.58M | $43.07M | $31.99M | $25.17M | $36.96M |
| Accounts Receivable | $120.53M | $128.30M | $130.40M | $132.37M | $118.08M | $127.39M | $121.92M | $137.31M | $125.54M | $122.79M |
| Inventory | $83.19M | $82.24M | $96.27M | $96.47M | $94.05M | $92.47M | $90.03M | $87.61M | $97.00M | $91.33M |
| Accounts Payable | $24.05M | $10.93M | $26.65M | $24.25M | $19.20M | $23.69M | $16.85M | $24.44M | $19.10M | $23.04M |
| Current Assets | $249.81M | $272.84M | $280.90M | $275.20M | $249.37M | $275.61M | $298.69M | $308.88M | $265.90M | $268.00M |
| Total Assets | $650.54M | $683.56M | $701.59M | $706.79M | $691.41M | $727.96M | $769.49M | $792.17M | $794.24M | $810.91M |
| Current Liabilities | $148.09M | $160.38M | $161.75M | $185.68M | $174.75M | $210.40M | $211.49M | $231.46M | $173.32M | $175.50M |
| Long-term Debt | $253.33M | $278.95M | $311.33M | $297.88M | $308.59M | $308.29M | $345.02M | $344.72M | $355.43M | $367.00M |
| Total Liabilities | $416.27M | $455.11M | $494.34M | $505.49M | $505.94M | $542.35M | $582.66M | $603.11M | $576.81M | $589.79M |
| Stockholders' Equity | $188.90M | $184.10M | $166.10M | $161.24M | $148.14M | $147.94M | $148.74M | $150.94M | $171.28M | $173.59M |
| Retained Earnings | ($331.82M) | ($334.93M) | ($349.68M) | ($352.84M) | ($360.30M) | ($355.08M) | ($354.92M) | ($350.10M) | ($326.11M) | ($321.54M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $8.93M | - | - | - | ($19.33M) | - | - | - | ($6.00M) | - |
| Investing Cash Flow | ($574.0K) | - | - | - | ($826.0K) | - | - | - | ($1.00M) | - |
| Financing Cash Flow | ($23.14M) | - | - | - | $947.0K | - | - | - | ($4.24M) | - |
| CapEx | $574.0K | - | - | - | $826.0K | - | - | - | $291.0K | - |
| Free Cash Flow | $8.36M | - | - | - | ($20.16M) | - | - | - | ($6.30M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 68.7% | - | 68.0% | 69.1% | 67.0% | - | 67.3% | 68.5% | 68.3% | - |
| Operating margin | 6.4% | - | 8.1% | 12.4% | 3.9% | - | 2.9% | -19.4% | 4.1% | - |
| EBITDA margin | 14.9% | - | 9.1% | 13.4% | 13.5% | - | 4.4% | -18.1% | 13.2% | - |
| Net margin | 2.4% | - | 2.3% | 5.1% | -2.1% | - | -3.5% | -15.9% | -3.5% | - |
| Free cash flow margin | 6.3% | - | - | - | -16.3% | - | - | - | -4.9% | - |
| FCF / Net income | 2.69 | - | - | - | 7.64 | - | - | - | 1.38 | - |
| R&D / Revenue | 1.9% | - | 2.1% | 2.1% | 2.4% | - | 2.7% | 2.6% | 2.0% | - |
| SG&A / Revenue | 59.3% | - | 56.7% | 53.6% | 59.3% | - | 58.4% | 62.7% | 60.6% | - |
| Effective tax rate | 15.5% | - | 17.4% | 12.2% | - | - | - | - | - | - |
| Return on assets | 0.5% | - | 0.4% | 1.1% | -0.4% | - | -0.6% | -3.0% | -0.6% | - |
| Return on equity | 1.6% | - | 1.9% | 4.6% | -1.8% | - | -3.2% | -15.9% | -2.7% | - |
| Return on invested capital | 1.6% | - | 1.9% | 3.5% | 0.8% | - | 0.7% | -4.7% | 0.8% | - |
| Liquidity | ||||||||||
| Current ratio | 1.69 | 1.70 | 1.74 | 1.48 | 1.43 | 1.31 | 1.41 | 1.33 | 1.53 | 1.53 |
| Quick ratio | 1.13 | 1.19 | 1.14 | 0.96 | 0.89 | 0.87 | 0.99 | 0.96 | 0.97 | 1.01 |
| Cash ratio | 0.24 | 0.32 | 0.26 | 0.18 | 0.13 | 0.20 | 0.20 | 0.14 | 0.15 | 0.21 |
| Leverage | ||||||||||
| Debt / Equity | 1.34 | 1.52 | 1.87 | 1.85 | 2.08 | 2.08 | 2.32 | 2.28 | 2.08 | 2.11 |
| Debt / Assets | 0.39 | 0.41 | 0.44 | 0.42 | 0.45 | 0.42 | 0.45 | 0.44 | 0.45 | 0.45 |
| Debt / EBITDA | 12.91 | - | 24.61 | 15.04 | 18.44 | - | 56.20 | - | 20.77 | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 3.44 | 3.71 | 4.22 | 4.38 | 4.67 | 4.92 | 5.17 | 5.25 | 4.64 | 4.67 |
| Liabilities / Assets | 0.64 | 0.67 | 0.70 | 0.72 | 0.73 | 0.75 | 0.76 | 0.76 | 0.73 | 0.73 |
| Efficiency | ||||||||||
| Asset turnover | 0.20 | - | 0.20 | 0.21 | 0.18 | - | 0.18 | 0.19 | 0.16 | - |
| Inventory turnover | 0.50 | - | 0.46 | 0.47 | 0.43 | - | 0.50 | 0.54 | 0.42 | - |
| Days sales outstanding | 333d | - | 343d | 327d | 348d | - | 320d | 331d | 354d | - |
| Days inventory outstanding | 735d | - | 791d | 773d | 841d | - | 724d | 672d | 862d | - |
| Days payable outstanding | 212d | - | 219d | 194d | 172d | - | 135d | 187d | 170d | - |
| Cash conversion cycle | 855d | - | 915d | 906d | 1017d | - | 908d | 816d | 1046d | - |
| Valuation | ||||||||||
| P / E | 223.5x | - | 133.2x | 61.5x | - | - | - | - | - | - |
| P / B | 3.3x | - | 2.8x | 2.9x | 4.0x | - | 5.1x | 2.4x | 1.9x | - |
| P / S | 4.7x | - | 3.3x | 3.1x | 4.8x | - | 5.5x | 2.4x | 2.5x | - |
| EV / EBITDA | 43.0x | - | 57.5x | 36.8x | 52.7x | - | 172.9x | - | 38.6x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 6.6% | - | -0.2% | -2.4% | -4.3% | - | 15.0% | 10.3% | 8.7% | - |
| Revenue CAGR (3y) | 3.5% | - | 2.5% | 1.7% | 1.8% | - | 8.5% | 37.6% | 16.5% | - |
| Revenue CAGR (5y) | 10.1% | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 9.3% | - | 0.7% | -1.5% | -6.0% | - | 18.6% | 16.3% | 19.6% | - |
| Operating income growth (YoY) | 72.8% | - | 176.2% | - | -8.6% | - | 68.5% | - | - | - |
| Net income growth (YoY) | - | - | - | - | 42.3% | - | 33.9% | -551.8% | 96.7% | - |
| EPS growth (YoY) | - | - | - | - | 42.9% | - | 41.7% | -516.7% | 96.9% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | -220.2% | - | - | - | -488.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 27.5% | 24.4% | 11.7% | 6.8% | -13.5% | -14.8% | -16.2% | -17.6% | -9.1% | -45.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$568.09M totalUSSegment$502.10M · 88.4%
International Segment$65.99M · 11.6%
Product / service
$502.10M totalPain Treatments$248.24M · 49.4%
Surgical Solutions$180.44M · 35.9%
Restorative Therapies$73.42M · 14.6%
Geographic
$568.09M totalUS$502.10M · 88.4%
Non Us$65.99M · 11.6%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Bioventus Inc. against the 5 most active filers in the same SIC group.